Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.
Ontology highlight
ABSTRACT: Approximately 5% of individuals infected with hepatitis B virus (HBV) are coinfected with hepatitis D virus (HDV). Chronic HBV/HDV coinfection is associated with an unfavourable outcome, with many patients developing liver cirrhosis, liver failure and eventually hepatocellular carcinoma within 5-10 years. The identification of the HBV/HDV receptor and the development of novel in vitro and animal infection models allowed a more detailed study of the HDV life cycle in recent years, facilitating the development of specific antiviral drugs. The characterisation of HDV-specific CD4+ and CD8+T cell epitopes in untreated and treated patients also permitted a more precise understanding of HDV immunobiology and possibly paves the way for immunotherapeutic strategies to support upcoming specific the
SUBMITTER: Urban S
PROVIDER: S-EPMC8355886 | biostudies-literature | 2021 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA